Lung Cancer Screening
Introducing PAULA’s Test
160,000 AMERICANS DIE EVERY YEAR
Each year, 160,000 Americans die of lung cancer. Paula Shore was among them. Though she smoked early in life, she had been cigarette-free for over 22 years when she was diagnosed. In fact, she had adopted a healthy lifestyle and undergone the screening tests appropriate for her gender and age. Unfortunately, she still contracted lung cancer, and by the time it was discovered, it showed up as a metastasis of her skin, and there were no treatments available that could save her. Back then, the blood tests available simply were not able to detect her cancer early when surgery could have saved her life.
Today, there is an early detection test that can identify lung cancer even when no symptoms are present! The test was developed by 20/20 GeneSystems, Inc. in Rockville MD, and is known as the PAULA’s Test. The name serves both as an acronym indicating the nature of the test (i.e. Protein Assays Using Lung Cancer Analytes), and to honor one of the Foundation’s namesakes, Paula Shore. Individuals or physicians interested in having the test may obtain additional information at www.paulastest.com.
If PAULA’s Test were performed annually on patients who present a high risk for contracting lung cancer, it is likely that not only would cancer be detected early, but the chances for survival would be much more favorable.
Although lung cancer has not received as much attention as several other cancers, the sad fact is it causes more deaths than the next three most common cancers combined. Smoking is the most common cause. Former smokers remain at increased (but slowly decreasing) risk for several decades after they quit.
In the United States, where many individuals have stopped smoking, the largest group of persons now developing lung cancer are former smokers. We highly recommend the PAULA’s Test yearly for former smokers as well as current smokers. Individuals over the age of 50 with a history of 20 pack-years or more are particularly vulnerable.
Lung cancer may occur as a result of secondhand smoke and pollution, particularly in parts of the world where significant indoor and outdoor pollution exist. In the United States, it has been estimated that 20% of women who develop lung cancer never smoked.
The United States Preventive Services Task Force has recently recommended Spiral CT scanning for certain persons at high risk of lung cancer. There is not yet sufficient data for the task force to issue a statement on the PAULA’s Test. In theory, however, there could be multiple advantages to the PAULA’s Test if preliminary results are confirmed with additional experience. These include reduced exposure to radiation, greater availability of the test, far fewer false positive results, and potentially earlier detection of lung cancer which could result in greater survival. It has previously been demonstrated that blood test markers have detected evidence of lung cancer before it was evident on x-ray studies.
Get the latest updates on our research.
Delivering Cures for Cancer
4701 Randolph Rd.
Rockville MD 20852
*All donations are tax deductible.
OR DONATE ONLINE
support us and changethe future of cancer.
Drs. Ronald Shore and Joseph Fox, who founded Delivering Cures for Cancer and The Paula Shore/Sari Fox Foundation, receive no salary, income or other compensation from the Foundation. Their donations have covered the majority of the start up costs including website, legal, accounting, administrative, and promotions expenses. Dr. Shore, whose skin cancer screening program is described on this website, has helped to educate fellow dermatologists and other medical personnel on how to perform highly effective skin cancer screening through international lectures and publications, largely at personal expense. Honoraria for his presentations, if provided, have been returned to the institution (e.g. University of Pennsylvania), or given to charity (e.g. The Society for Dermatologic Physician Assistants). He receives no other compensation from industry, academic institutions or other entities. Dr. Shore has volunteered his time and knowledge on screening to 20/20 GeneSystems, Inc., the developer of the PAULAs Test, a new blood test for early detection of lung cancer. He has also served on its Medical Advisory Board. He has received no remuneration for these forms of assistance. Dr. Shore and Dr. Fox were each approached by 20/20 GeneSystems, Inc. to purchase shares to help the company continue its research, and both agreed to do so. Their investments in the company, in each case, represent well under 1% of total investments. Neither physician holds any controlling or voting position in the company, nor draws any salary or other compensation. Dr. Shore and Dr. Fox, who for several years have spoken to various individuals, organizations and government personnel to try to advance Dr. Esther Chang’s research, were each approached by SynerGeneTherape